<DOC>
	<DOCNO>NCT02293395</DOCNO>
	<brief_summary>The purpose study estimate risk bleed rivaroxaban , compare acetylsalicylic acid ( ASA ) , addition single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist ( P2Y12 inhibitor agent : clopidogrel ticagrelor ) , participant recent acute coronary syndrome ( ACS : include ST segment elevation myocardial infarction [ STEMI ] non-ST-segment elevation acute coronary syndrome [ NSTE-ACS ] ) .</brief_summary>
	<brief_title>A Study Compare Safety Rivaroxaban Versus Acetylsalicylic Acid Addition Either Clopidogrel Ticagrelor Therapy Participants With Acute Coronary Syndrome</brief_title>
	<detailed_description>This prospective , randomize ( study drug assign chance ) , double-blind ( neither physician participant know treatment participant receives ) , active-controlled ( study experimental treatment procedure compare standard treatment procedure ) , parallel group ( group participant treat time ) , multicenter ( one hospital medical school team work medical research study ) study participant recent ACS ( STEMI NSTE-ACS ) . All eligible participant receive background treatment ASA plus clopidogrel ( Stratum 1 ) ASA plus ticagrelor ( Stratum 2 ) randomly assign either receive ASA rivaroxaban background P2Y12 receptor antagonist treatment . This study include 3 phase : Screening Phase ( 10 day , study start Day 1 ) , Double-blind Treatment Phase ( either 180 day randomization last enrol participant study Day 360 , whichever occur early ) , Follow-up Phase ( 30 day ) . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Participants , 18 year old , must symptoms suggestive acute coronary syndrome ( ACS ) ( angina , symptom think equivalent ) within 48 hour hospital presentation , develop ACS hospitalize , diagnosis : ) ST segment elevation myocardial infarction ( STEMI ) ; b ) nonSTsegment elevation acute coronary syndrome ( NSTEACS ) . However , participant 54 year age young must also either diabetes mellitus history prior myocardial infarction ( MI ) , addition present ACS event Participant must randomize within screen window 10 day hospital admission index ACS event . Participant receive acute phase treatment index ACS , intravenous anticoagulant antiplatelet , receive maintenance dual antiplatelet therapy ( DAPT ) either clopidogrel plus acetyl salicylic acid ( ASA ) , ticagrelor plus ASA , intent continue treatment platelet adenosine diphosphate P2Y12 receptor antagonist ( P2Y12 inhibitor ) randomization Participants must agree provide pharmacogenomics deoxyribonucleic acid ( DNA ) sample Participant condition , opinion investigator , contraindicate anticoagulant therapy would unacceptable risk Participant prior stroke etiology transient ischemic attack ( TIA ) Participant receive thrombolytic therapy treatment index ACS event enrol ticagrelor stratum Participant anticipate need chronic administration omeprazole esomeprazole concomitantly clopidogrel Participant know allergy intolerance ASA rivaroxaban</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>Unstable angina</keyword>
	<keyword>Acetylsalicylic acid</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>JNJ-39039039</keyword>
	<keyword>Bay 59-7939</keyword>
	<keyword>Xarelto</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Plavix</keyword>
	<keyword>Brilinta</keyword>
	<keyword>Effient</keyword>
</DOC>